<p>Rocket Pharmaceuticals（納斯達克代碼：RCKT - 獲取免費報告）在週五向客户和投資者發佈的研究報告中，投資分析師 Leerink Partners 將其目標價格從 9.00 美元下調至 7.00 美元，Benzinga 報道。該券商目前對這家生物技術公司的股票給予 “市場表現” 評級。Leerink Partners 的目標價格意味着該股票相較於之前的收盤價有 118.41% 的潛在上漲空間。</p>
<p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
<p>其他一些股票分析師也對 RCKT 發表了評論。瑞銀集團將 Rocket Pharmaceuticals 的目標價格從 12.00 美元下調至 5.00 美元，並在 6 月 17 日的研究報告中對該股票給予 “買入” 評級。Canaccord Genuity Group 將 Rocket Pharmaceuticals 的目標價格從 11.00 美元下調至 10.00 美元，並在 7 月 25 日的報告中對該股票給予 “買入” 評級。Chardan Capital 在 8 月 20 日的報告中重申了對 Rocket Pharmaceuticals 的 “買入” 評級，並設定了 11.00 美元的目標價格。美國銀行在 8 月 20 日的報告中將 Rocket Pharmaceuticals 的評級從 “中性” 上調至 “買入”，並將該股票的目標價格從 4.00 美元提高至 10.00 美元。最後，Needham &amp; Company LLC 在 7 月 24 日的報告中重申了對 Rocket Pharmaceuticals 的 “持有” 評級。八位股票研究分析師對該股票給予 “買入” 評級，八位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價格為 16.67 美元。</p>
<p><strong>閲讀我們最新的 RCKT 股票分析</strong></p>
<h2>Rocket Pharmaceuticals 股票表現</h2>
<p>Rocket Pharmaceuticals 的股票在週五下跌 0.01 美元，報 3.21 美元。該公司的股票交易量為 623,434 股，而其平均交易量為 3,511,637 股。該公司的市值為 3.4582 億美元，市盈率為-1.28，貝塔值為 0.60。該公司的速動比率為 6.39，流動比率為 6.39，債務與股本比率為 0.05。該公司的 50 日移動平均價格為 3.19 美元，200 日移動平均價格為 4.37 美元。Rocket Pharmaceuticals 的股價在過去一年內最低為 2.19 美元，最高為 18.89 美元。</p>
<p>Rocket Pharmaceuticals（納斯達克代碼：RCKT - 獲取免費報告）最近一次發佈財報是在 8 月 7 日。該生物技術公司報告本季度每股收益為（0.59 美元），低於市場共識預期的（0.57 美元），差額為（0.02 美元）。去年同期，該公司每股收益為（0.74 美元）。分析師平均預計 Rocket Pharmaceuticals 在本年度的每股收益為-2.83 美元。</p>
<h2>Rocket Pharmaceuticals 的內部活動</h2>
<p>在相關消息中，內部人士 Jonathan David Schwartz 在 8 月 14 日的交易中出售了 11,161 股該股票。這些股票的平均售價為 3.02 美元，總價值為 33,706.22 美元。出售後，該內部人士直接持有 224,094 股公司股票，價值 676,763.88 美元。這筆交易代表其持股比例減少了 4.74%。該出售在向 SEC 的法律文件中披露，文件可在此鏈接查看。此外，首席法律顧問 Martin Wilson 在 8 月 14 日的交易中出售了 12,109 股該股票。這些股票的平均售價為 3.02 美元，總交易額為 36,569.18 美元。出售完成後，首席法律顧問持有 137,054 股公司股票，價值 413,903.08 美元。這代表其持股比例減少了 8.12%。該出售的披露信息可以在這裏找到。在過去的九十天裏，內部人士共出售了價值 107,159 美元的 35,450 股公司股票。公司內部人士持有公司股票的 24.76%。</p>
<h2>Rocket Pharmaceuticals 的機構交易</h2>
<p>最近，一些對沖基金買入和賣出了該股票的股份。Victory Capital Management Inc.在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 16.1%。Victory Capital Management Inc.現在擁有 11,929 股該生物技術公司的股票，價值 80,000 美元，此前在上個季度又購買了 1,658 股。三菱 UFJ 資產管理有限公司在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 8.4%。三菱 UFJ 資產管理有限公司現在擁有 21,885 股該生物技術公司的股票，價值 146,000 美元，此前在上個季度又購買了 1,689 股。中國泛海資產管理有限公司在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 10.7%。中國泛海資產管理有限公司現在擁有 21,388 股該生物技術公司的股票，價值 143,000 美元，此前在上個季度又購買了 2,059 股。HighTower Advisors LLC 在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 16.6%。HighTower Advisors LLC 現在擁有 20,700 股該生物技術公司的股票，價值 138,000 美元，此前在上個季度又購買了 2,952 股。最後，亞利桑那州退休系統在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 15.3%。亞利桑那州退休系統現在擁有 22,852 股該生物技術公司的股票，價值 152,000 美元，此前在上個季度又購買了 3,026 股。目前 98.39% 的股票由機構投資者和對沖基金持有。</p>
<h2>Rocket Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Rocket Pharmaceuticals, Inc 及其子公司是一家處於後期階段的生物技術公司，專注於開發針對罕見且嚴重疾病的基因療法。它擁有三個臨牀階段的外源性慢病毒載體項目，分別針對範可尼貧血，這是一種導致骨髓中血細胞生產減少或產生有缺陷血細胞的遺傳缺陷；白細胞粘附缺陷-I，這是一種導致免疫系統功能失常的遺傳疾病；以及丙酮酸激酶缺乏症，這是一種罕見的紅細胞常染色體隱性遺傳病，導致慢性非球形溶血性貧血。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們認為比 Rocket Pharmaceuticals 更好的股票</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>Sandisk 在 118% 的 AI 推動上漲後仍然值得購買嗎？</li>
<li>投資建築類股票</li>
<li>為什麼 GlobalFoundries 剛剛成為地緣政治的權力遊戲</li>
<li>什麼是認沽期權成交量？</li>
<li>3 只通過回購推動可持續價格增長的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Rocket Pharmaceuticals 嗎？</h2>
<p>在你考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 Rocket Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Rocket制藥

<p>Leerink Partners 已將 Rocket Pharmaceuticals（NASDAQ:RCKT）的目標價從 9.00 美元下調至 7.00 美元，維持 “市場表現” 評級。此調整表明，相較於該股前一交易日的收盤價，潛在上漲幅度為 118.41%。其他分析師也調整了他們的目標價，瑞銀集團設定的目標為 5.00 美元，加拿大皇家銀行的目標為 10.00 美元。目前，Rocket Pharmaceuticals 的平均評級為 “持有”，共識目標價為 16.67 美元。該股交易價格為 3.21 美元，市值為 3.4582 億美元</p>

<p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) had its target price cut by investment analysts at Leerink Partners from $9.00 to $7.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a &#34;market perform&#34; rating on the biotechnology company's stock. Leerink Partners' target price points to a potential upside of 118.41% from the stock's previous close.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（納斯達克代碼：RCKT - 獲取免費報告）在週五向客户和投資者發佈的研究報告中，投資分析師 Leerink Partners 將其目標價格從 9.00 美元下調至 7.00 美元，Benzinga 報道。該券商目前對這家生物技術公司的股票給予 “市場表現” 評級。Leerink Partners 的目標價格意味着該股票相較於之前的收盤價有 118.41% 的潛在上漲空間。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准備大幅上漲的小型股</li>
</ul>
</div><p>A number of other equities analysts have also commented on RCKT. UBS Group reduced their price target on shares of Rocket Pharmaceuticals from $12.00 to $5.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, June 17th. Canaccord Genuity Group decreased their price objective on shares of Rocket Pharmaceuticals from $11.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, July 25th. Chardan Capital reissued a &#34;buy&#34; rating and set a $11.00 price objective on shares of Rocket Pharmaceuticals in a report on Wednesday, August 20th. Bank of America raised shares of Rocket Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and increased their price objective for the stock from $4.00 to $10.00 in a report on Wednesday, August 20th. Finally, Needham &amp; Company LLC reissued a &#34;hold&#34; rating on shares of Rocket Pharmaceuticals in a report on Thursday, July 24th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $16.67.</p>
<div class="lb-trans"><p>其他一些股票分析師也對 RCKT 發表了評論。瑞銀集團將 Rocket Pharmaceuticals 的目標價格從 12.00 美元下調至 5.00 美元，並在 6 月 17 日的研究報告中對該股票給予 “買入” 評級。Canaccord Genuity Group 將 Rocket Pharmaceuticals 的目標價格從 11.00 美元下調至 10.00 美元，並在 7 月 25 日的報告中對該股票給予 “買入” 評級。Chardan Capital 在 8 月 20 日的報告中重申了對 Rocket Pharmaceuticals 的 “買入” 評級，並設定了 11.00 美元的目標價格。美國銀行在 8 月 20 日的報告中將 Rocket Pharmaceuticals 的評級從 “中性” 上調至 “買入”，並將該股票的目標價格從 4.00 美元提高至 10.00 美元。最後，Needham &amp; Company LLC 在 7 月 24 日的報告中重申了對 Rocket Pharmaceuticals 的 “持有” 評級。八位股票研究分析師對該股票給予 “買入” 評級，八位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價格為 16.67 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on RCKT</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 RCKT 股票分析</strong></p>
</div><h2>Rocket Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股票表現</h2>
</div><p>Rocket Pharmaceuticals stock traded down $0.01 on Friday, hitting $3.21. The company's stock had a trading volume of 623,434 shares, compared to its average volume of 3,511,637. The firm has a market cap of $345.82 million, a P/E ratio of -1.28 and a beta of 0.60. The company has a quick ratio of 6.39, a current ratio of 6.39 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average price of $3.19 and a 200-day moving average price of $4.37. Rocket Pharmaceuticals has a one year low of $2.19 and a one year high of $18.89.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals 的股票在週五下跌 0.01 美元，報 3.21 美元。該公司的股票交易量為 623,434 股，而其平均交易量為 3,511,637 股。該公司的市值為 3.4582 億美元，市盈率為-1.28，貝塔值為 0.60。該公司的速動比率為 6.39，流動比率為 6.39，債務與股本比率為 0.05。該公司的 50 日移動平均價格為 3.19 美元，200 日移動平均價格為 4.37 美元。Rocket Pharmaceuticals 的股價在過去一年內最低為 2.19 美元，最高為 18.89 美元。</p>
</div><p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.02). During the same period last year, the company earned ($0.74) EPS. On average, equities analysts anticipate that Rocket Pharmaceuticals will post -2.83 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（納斯達克代碼：RCKT - 獲取免費報告）最近一次發佈財報是在 8 月 7 日。該生物技術公司報告本季度每股收益為（0.59 美元），低於市場共識預期的（0.57 美元），差額為（0.02 美元）。去年同期，該公司每股收益為（0.74 美元）。分析師平均預計 Rocket Pharmaceuticals 在本年度的每股收益為-2.83 美元。</p>
</div><h2>Insider Activity at Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的內部活動</h2>
</div><p>In related news, insider Jonathan David Schwartz sold 11,161 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $3.02, for a total value of $33,706.22. Following the sale, the insider directly owned 224,094 shares in the company, valued at $676,763.88. This trade represents a 4.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Martin Wilson sold 12,109 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $3.02, for a total transaction of $36,569.18. Following the completion of the sale, the general counsel owned 137,054 shares in the company, valued at $413,903.08. This represents a 8.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,450 shares of company stock worth $107,159 in the last ninety days. Company insiders own 24.76% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Jonathan David Schwartz 在 8 月 14 日的交易中出售了 11,161 股該股票。這些股票的平均售價為 3.02 美元，總價值為 33,706.22 美元。出售後，該內部人士直接持有 224,094 股公司股票，價值 676,763.88 美元。這筆交易代表其持股比例減少了 4.74%。該出售在向 SEC 的法律文件中披露，文件可在此鏈接查看。此外，首席法律顧問 Martin Wilson 在 8 月 14 日的交易中出售了 12,109 股該股票。這些股票的平均售價為 3.02 美元，總交易額為 36,569.18 美元。出售完成後，首席法律顧問持有 137,054 股公司股票，價值 413,903.08 美元。這代表其持股比例減少了 8.12%。該出售的披露信息可以在這裏找到。在過去的九十天裏，內部人士共出售了價值 107,159 美元的 35,450 股公司股票。公司內部人士持有公司股票的 24.76%。</p>
</div><h2>Institutional Trading of Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的機構交易</h2>
</div><p>Several hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its holdings in shares of Rocket Pharmaceuticals by 16.1% during the first quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company's stock worth $80,000 after buying an additional 1,658 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Rocket Pharmaceuticals by 8.4% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 21,885 shares of the biotechnology company's stock valued at $146,000 after purchasing an additional 1,689 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Rocket Pharmaceuticals by 10.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 21,388 shares of the biotechnology company's stock valued at $143,000 after purchasing an additional 2,059 shares in the last quarter. HighTower Advisors LLC raised its stake in Rocket Pharmaceuticals by 16.6% in the first quarter. HighTower Advisors LLC now owns 20,700 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 2,952 shares in the last quarter. Finally, Arizona State Retirement System raised its stake in Rocket Pharmaceuticals by 15.3% in the first quarter. Arizona State Retirement System now owns 22,852 shares of the biotechnology company's stock valued at $152,000 after purchasing an additional 3,026 shares in the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近，一些對沖基金買入和賣出了該股票的股份。Victory Capital Management Inc.在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 16.1%。Victory Capital Management Inc.現在擁有 11,929 股該生物技術公司的股票，價值 80,000 美元，此前在上個季度又購買了 1,658 股。三菱 UFJ 資產管理有限公司在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 8.4%。三菱 UFJ 資產管理有限公司現在擁有 21,885 股該生物技術公司的股票，價值 146,000 美元，此前在上個季度又購買了 1,689 股。中國泛海資產管理有限公司在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 10.7%。中國泛海資產管理有限公司現在擁有 21,388 股該生物技術公司的股票，價值 143,000 美元，此前在上個季度又購買了 2,059 股。HighTower Advisors LLC 在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 16.6%。HighTower Advisors LLC 現在擁有 20,700 股該生物技術公司的股票，價值 138,000 美元，此前在上個季度又購買了 2,952 股。最後，亞利桑那州退休系統在第一季度將其在 Rocket Pharmaceuticals 的持股增加了 15.3%。亞利桑那州退休系統現在擁有 22,852 股該生物技術公司的股票，價值 152,000 美元，此前在上個季度又購買了 3,026 股。目前 98.39% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Rocket Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 及其子公司是一家處於後期階段的生物技術公司，專注於開發針對罕見且嚴重疾病的基因療法。它擁有三個臨牀階段的外源性慢病毒載體項目，分別針對範可尼貧血，這是一種導致骨髓中血細胞生產減少或產生有缺陷血細胞的遺傳缺陷；白細胞粘附缺陷-I，這是一種導致免疫系統功能失常的遺傳疾病；以及丙酮酸激酶缺乏症，這是一種罕見的紅細胞常染色體隱性遺傳病，導致慢性非球形溶血性貧血。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Is Sandisk Still a Buy After 118% AI-Fueled Surge?</li>
<li>Investing in Construction Stocks</li>
<li>Why GlobalFoundries Just Became a Geopolitical Power Play</li>
<li>What is Put Option Volume?</li>
<li>3 Stocks Using Buybacks to Drive Sustainable Price Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Rocket Pharmaceuticals 更好的股票</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>Sandisk 在 118% 的 AI 推動上漲後仍然值得購買嗎？</li>
<li>投資建築類股票</li>
<li>為什麼 GlobalFoundries 剛剛成為地緣政治的權力遊戲</li>
<li>什麼是認沽期權成交量？</li>
<li>3 只通過回購推動可持續價格增長的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Rocket Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Rocket Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 Rocket Pharmaceuticals 並不在名單上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rocket Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Leerink Partners 的分析師將 Rocket 製藥（NASDAQ:RCKT）的目標價下調至 7.00 美元